Identification of individuals at risk of hepatocellular carcinoma: screening for clinically significant liver fibrosis in patients with T2DM

Figures & data

Figure 1. Screening for clinically significant liver fibrosis in patients with type 2 diabetes.

Note: The figure illustrates key risk factors for liver fibrosis, and the use of biomarkers and vibration-controlled transient elastography for the detection of clinically significant fibrosis and cirrhosis. The figure highlights that: (a) patients with low stage fibrosis should be targeted toward lifestyle measures proven to be clinically effective for amelioration of early liver disease in NAFLD, and treatment with GLP-1 receptor agonists to facilitate weight loss, treat hyperglycemia, and decrease risk of cardiovascular disease; and (b) patients with cirrhosis should be referred for HCC surveillance.